[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100454485":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":50,"collaborators":54,"id":99,"slug":10,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":10,"enrollmentInfo":108,"targetDuration":111,"studyType":112,"phases":10,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Second Xiangya Hospital of Central South University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Advanced NSCLC patients with long-term benefit after first-line immunotherapy (Tumor-informed group)",null,"The ctDNA detection will be performed using a tumor-informed analysis approach. This method requires the availability of tumor tissue samples or a fixed-panel next-generation sequencing (NGS) test.",[13],"Diagnostic Test: ctDNA detection",{"label":15,"type":10,"description":16,"interventionNames":17},"Advanced NSCLC patients with long-term benefit after first-line immunotherapy (Tumor-agnostic group)","The ctDNA detection will be performed using a tumor-agnostic analysis. This method does not require tumor tissue samples or an NGS testing panel, or in cases where tissue samples are available but fail to meet quality control standards.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","ctDNA detection","High-depth sequencing method is used to detecting ctDNA.",[15,9],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Chunhong Hu, professor","CONTACT","+86 13508486908","huchunh5829@126.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Oncology Department，Second Xiangya Hospital of Central South University","RECRUITING","Changsha","Hunan","410011","China",{"type":39,"coordinates":40},"Point",[41,42],112.97087,28.19874,{"lat":42,"lon":41},[45,46],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":47,"role":27,"phone":48,"phoneExt":10,"email":49},"Fang Wu, professor","13574858332","wufang4461@csu.edu.cn",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Fang Wu","Associate Professor",[55,57,59,62,64,66,68,70,72,74,76,78,80,82,84,86,88,90,92,95,97],{"name":56,"class":6},"Sun Yat-Sen University Cancer Center",{"name":58,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":60,"class":61},"Fujian Cancer Hospital","OTHER_GOV",{"name":63,"class":6},"Third Affiliated Hospital of Third Military Medical University",{"name":65,"class":6},"Xiangya Hospital of Central South University",{"name":67,"class":6},"Qinghai Province Fifth People's Hospital",{"name":69,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":71,"class":6},"Zhejiang Provincial People's Hospital",{"name":73,"class":6},"Hunan Province Tumor Hospital",{"name":75,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"name":77,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"name":79,"class":6},"Zhejiang Cancer Hospital",{"name":81,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":83,"class":6},"Inner Mongolia People's Hospital",{"name":85,"class":6},"Guizhou Provincial People's Hospital",{"name":87,"class":6},"The Third Xiangya Hospital of Central South University",{"name":89,"class":6},"Yueyang Central Hospital",{"name":91,"class":6},"ZhuZhou Central Hospital",{"name":93,"class":94},"Zhangjiajie Affiliated Hospital of Hunan Normal University","UNKNOWN",{"name":96,"class":6},"Loudi Central Hospital",{"name":98,"class":94},"Chang Sha First Hospital","100454485",false,"NCT05198154","ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC","A Multicenter, Prospective Clinical Study of Circulating Tumor DNA Analysis to Monitor the Risk of Progression After Long-term Benefit to First-line Immunotherapy in Patients With Advanced NSCLC (CR1STAL)","CR1STAL","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Advanced non-small cell lung cancer (stage IIIB-IV), pathological types limited to squamous cell carcinoma or non-squamous cell carcinoma, driver gene mutations (EGFR\u002FALK\u002FROS1) were negative\n* General condition: ECOG score 0 or 1\n* First-line monotherapy or combination immunotherapy\n* The long-term benefit of immunotherapy was defined as PFS=12months\n* Tumor tissue samples can be obtained at the time of enrollment, and at least 5 \\~ 10 sections can be generated, and the pathological report indicates that the overall tumor content is not less than 10% or NGS testing with a fixed-panel is available; or no tumor tissue is available.\n* At least one measurable lesion (except patients with CR after first-line treatment) can be evaluated according to RECIST1.1 standard.\n* Have self-awareness, be able to understand the research scheme and voluntarily participate in the study, and can sign the informed consent form\n* Have good compliance, be able to cooperate with the collection of specimens from each node and provide corresponding clinical information.\n\nExclusion Criteria:\n\n* Serious primary diseases of the heart, liver and kidney\n* Other malignant tumors within 3 years prior to diagnosis of NSCLC\n* Women in pregnancy and lactation\n* The active stage of human immunodeficiency virus (HIV) infection\n* Patients with active systemic infection, pneumonia, tuberculosis, pericarditis\n* Patients who cannot understand the content of the experiment and cannot cooperate and refuse to sign informed consent.","ALL","18 Years",{"count":109,"type":110},100,"ESTIMATED","3 Years","OBSERVATIONAL","This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)",[115],"Advanced Lung Non-Small Cell Carcinoma",[117,118,119,120,121,122],"ctDNA","advanced lung cancer","first-line immunotherapy","the risk of progression","minimal residual disease (MRD)","long-term benefit","2025-04-17",{"date":125,"type":126},"2025-04-23","ACTUAL",{"date":128,"type":126},"2022-01-24",{"date":130,"type":110},"2025-12-30",{"name":52,"class":6},1]